

AL



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 174 129 A1**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
23.01.2002 Bulletin 2002/04

(51) Int Cl.7: **A61K 31/00, A61K 31/4439,
A61P 35/00**

(21) Application number: **00114909.5**

(22) Date of filing: **17.07.2000**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**
Designated Extension States:
AL LT LV MK RO SI

(72) Inventors:
• **Zenner, Hans Peter, Prof. Dr. med.**
72070 Tübingen (DE)
• **Simon, Christian, Dr.**
72076 Tübingen (DE)

(71) Applicants:
• **Zenner, Hans Peter, Prof. Dr. med.**
72070 Tübingen (DE)
• **Simon, Christian, Dr.**
72076 Tübingen (DE)

(74) Representative:
**Patentanwälte Ruff, Wilhelm, Beier, Dauster &
Partner**
Postfach 10 40 36
70035 Stuttgart (DE)

(54) **Use of a matrix-metalloprotease inhibitor for the treatment of cancer**

(57) The invention relates to the use of an active agent, particularly an inhibitor, in treating cancer by influencing, preferably inhibiting the expression of matrix-metalloproteases. The targets for this active agent can especially relate to downstream regulators of the matrix-

metalloprotease 9 (MMP-9) signal transduction pathway. According to the invention, especially inhibitors of p38beta and p38gamma as also of mitogen-activated kinase kinase 6 (MKK6) and mitogen-activated kinase kinase 3 (MKK3) can be applied.

EP 1 174 129 A1

PT3005

Description

[0001] The invention relates to the use of an active agent, particularly an inhibitor, of matrix-metalloproteinases expression. More specifically, this invention relates to the use of such agents in connection with the treatment of cancer, especially cancer invasion.

[0002] As is known, the degradation of the extracellular matrix is a very complex process and it is part of many pathological and physiological processes. Thereby, the proteolytic degradation of the extracellular matrix plays a crucial role in cancer invasion as also in non-neoplastic tissue remodelling processes. The invasive phenotype of cancer critically depends on the activity and expression of several proteases. The role of the matrix-metalloproteinase enzymes in this tumor cell-mediated extracellular matrix proteolysis is well established. One of these matrix-metalloproteinases is the MR 92,000 type IV collagenase (MMP-9). MMP-9 degrades the basement membrane, a structure that is largely composed of type IV collagen and which normally separates the epithelial from the stromal compartment (1, 2). Many growth factors induce expression of MMP-9 and other proteases by binding to transmembrane tyrosine receptors which in turn activate signal transduction pathways (3, 4). However, some cell lines produce large amounts of proteases even in the absence of such growth factors, suggesting a constitutive activation of signaling cascades as one underlying mechanism (5). In fact, constitutive activation of signal transduction pathways has been described for renal cell carcinomas, leukemia's as well as numerous other cancers. In connection with these constitutive activation of signal transduction pathways reference is made to the publications of H. Oka et al. and to S.C. Kim et al. (6, 7).

[0003] It is well known by those who are skilled in the art that the stress- and mitogen-activated protein kinases (SAPK and MAPK) play a central role in signaling pathways. There are three major subfamilies including p38/RK, JNK/SAPK, and p42/p44 MAPK's/ERK's. In general ERK's are stimulated by mitogens and differentiative factors, while JNK and p38 are activated by environmental stress such as ultraviolet light, osmotic stress but also inflammatory cytokines. All three subfamilies regulate apoptosis, ERK's are negative but JNK's and p38's are positive regulators (8). So far four human isoforms of p38 have been cloned: p38alpha (9), p38beta (10), p38gamma (11), which also has been termed SAPK3 or ERK6 and p38delta (12), also termed SAPK4. The alpha- and beta-isoforms are predominantly involved in mediating proinflammatory signals to the nucleus and regulate apoptosis (8). p38gamma has been implicated to play a role in muscle development and response to hypoxic stress (13, 14). p38alpha and -beta are widely distributed in human tissues, their expression was found to be most abundant in brain and heart (10). SAPK3 is predominantly present in skeletal muscle (15, 16). Little is known about the function of

SAPK4. High levels of expression were found in salivary, pituitary and adrenal gland tissue (12).

[0004] Important upstream regulators of p38 isoforms include the protein kinases MKK6 and MKK3.

[0005] Findings and investigations up to now concerning the involvement of matrix-metalloproteinases in cancer invasion and metastasis have focused on the functions of the various matrix-metalloproteinases enzyme domains and their interactions with inhibitor domains. For instance it is known that the proteolytic activity of the matrix-metalloproteinases involved in extracellular matrix degradation must be precisely regulated by their endogenous protein inhibitors, the tissue inhibitors of metalloproteinases (TIMPs). These tissue inhibitors of metalloproteinases play also an important role in matrix degradation by tumor cells. The activity of TIMP and MMP was analysed in several carcinomas, for instance in renal cell carcinoma as also in gastric cancer. In connection with these studies reference is made to the publications of A. Kugler and G.I. Murray et al. (17, 18). These tissue inhibitors of metalloproteinases are a family of secreted proteins that play a crucial role in the regulation of the activity of the secreted metalloproteinases. Up to now three of them are characterized (TIMP1, TIMP2 and TIMP3). They influence the activation of the prometalloproteinases and act to modulate proteolysis of extracellular matrix, notably during tissue remodelling and inflammatory processes. A characterization of these tissue inhibitors of matrix-metalloproteinases, appears in the publication of D.T. Denhardt et al. (19). There are also synthetic matrix-metalloproteinases inhibitors like marimastat (BB-2516), a butanediamid-derivative with the IC₅₀ value in the micromolar range. C. Simon et al. (20) demonstrated that the enhanced MMP-9 secretion and in-vitro invasiveness in a human squamous cell carcinoma cell line (UM-SCC-1) after treatment with phorbol myristate acetate (PMA), a known tumor promoter widely used in the study of skin carcinogenesis (reviewed in (21)), could be inhibited by using the general p38 inhibitor SB 203580.

[0006] It has now surprisingly been found that the constitutive activity of the p38 as also the MKK6 and/or MKK3 pathway plays a crucial role in the high-level expression of MMP-9 in cancer cells. As a result of these unexpected findings, the use of active agents which are targeted/directed against downstream regulators of MMP-9 expression for the treatment of cancer, especially cancer invasion is made possible.

[0007] Thus, the problem of the invention of making available active agents for the treatment of cancer, is solved by the use according to claims 1 and 2. Preferred embodiments are given in the dependent claim 3 to 17. The content of all these claims is hereby incorporated into the description by reference.

[0008] According to the invention, at least one active agent is used for influencing, particularly inhibiting the expression of matrix-metalloproteinases in eukaryotic cells for the treatment of cancer. This in particular also

covers the use of such active agent for producing a corresponding medicament or a corresponding pharmaceutical composition. According to the present invention, the active agent can optionally be used in the form of its pharmaceutically acceptable salts and optionally together with a pharmaceutically acceptable carrier.

[0009] The active agents used according to the present invention are those which preferably influence, particularly inhibit the above-mentioned matrix-metalloproteases involved with cancer, preferably cancer invasion. According to the invention one preferred matrix-metalloprotease involved in cancer invasion is the matrix-metalloprotease 9.

[0010] In one preferred embodiment of this invention the active agent used is preferably targeted against at least one member of matrix-metalloprotease signal transduction pathways, particularly against one member of the MMP-9 signal transduction pathway. One preferred member of this MMP-9 signal transduction pathway is the so-called p38 protein family. In the use according to this invention one of these p38 proteins is the p38beta protein, another preferred member according to the use of the present invention is the p38gamma (SAPK3 or PRK6) protein. Another preferred target for the active agent according to the invention is the mitogen-activated kinase kinase family. Two preferred members of this mitogen-activated kinase kinase family are the mitogen-activated kinase kinase 6 (MKK6) and the mitogen-activated kinase kinase 3 (MKK3). In the use according to the invention one member of the MMP-9 signal transduction pathway can be targeted alone by the active agent, but there can also be a random combination of two or three or even more different members of the MMP-9 signal transduction pathway which are targeted by the active agent.

[0011] In another preferred embodiment it is optionally also possible that an activator, regulator and/or a biological precursor of the matrix-metalloprotease signal transduction pathway, preferably of the MMP-9 signal transduction pathway, is targeted and/or influenced by the active agent. These activators, regulators and/or biological precursors may be e.g. kinases which are known to be involved in the regulation of the enzymatic activity of proteases, transcriptional factors which are responsible for the expression level of proteases, proteases which are responsible for the activation of prometalloproteases or tissue inhibitors, or even up to date unknown compounds which can be influenced by the active agent.

[0012] According to the invention it is possible to use known or also novel active agents. In one preferred embodiment of the invention the active agent is a compound with specific inhibitory capacity against at least one member of the matrix-metalloprotease signal transduction pathway, preferably against the MMP-9 signal transduction pathway. This active agent is preferably a comparably small molecule of low molecular weight (MW), especially with a MW < 1000. It is further pre-

ferred, if such active agent is an imidazole derivative. Such imidazole derivatives, like SB 203580 (MW 377,4) or SB 202190 (MW 331,3) which are both obtainable from Calbiochem, San Diego, Ca, USA, are known to be potent inhibitors of kinase expression. In another preferred embodiment of this invention, the active agent is an inhibitor of p38 proteins. This can be a known or also a further novel inhibitor of p38 proteins. In another preferred embodiment of this invention, the active agent is an inhibitor of the mitogen-activated kinase kinase family. This inhibitor can be a peptide inhibitor of the mitogen-activated kinase kinase family like the kinase dead mutants constructed with standard molecular biology techniques as used in this description or also a novel inhibitor compound. Several inhibitors are known and one can find a few of them in the publications of Y. Fukami et al., J.C. Lee et al., and D. Fabbro et al. (22-24).

[0013] In another preferred embodiment according to the present invention the active agent is an inhibitor of activators, regulators and/or biological precursors of the matrix-metalloprotease signal transduction pathway, which might be kinase inhibitors, transcription factors inhibitors, tissue inhibitors, proteases inhibitors and other known or novel inhibitors of the matrix-metalloprotease signal transduction pathway.

[0014] In another preferred embodiment according to the invention the active agent is a polynucleotide which encodes a peptide or a polypeptide that inhibits the expression of matrix-metalloproteases, preferably inhibits p38 and/or mitogen-activated kinase kinase activity. This peptide can be e.g. a p38 kinase deficient mutants, a mitogen-activated kinase kinase dead mutant and other peptides known to those who are skilled in the art.

[0015] The invention can be used for treatment of all kinds of cancer, especially cancer with a overexpression of matrix-metalloproteases and therefore with a high invasiveness and metastasis of this cancer. A overexpression of MMP-9 was reported in squamous epithelial carcinomas of the head, neck, skin and stomach as also in fibrosarcomas of the stomach. An increased MMP-9 level was also found in the serum of patients with colon-, breast- and hepatocellular carcinomas. Therefore, among the treatable illnesses particular reference is made to the above noted cancers. As is generally known metastatic disease (but also often invasive tumor growth itself) limits the survival of cancer patients. The reasons of the constitutive activation of signal transduction pathways in cancer are up to now unknown. It might result from mutations of growth factor receptor genes such as gene amplifications or autocrine loops, i.e. expression of ligand and receptor in the same tissue. The above mentioned cancers are good targets for the active agent according to invention as cancer invasion is a vexing problem in these cancers.

[0016] According to the invention it is possible to select the administration form of the active agent. This form can be adapted to the age, sex or other characteristics of the patient, the severity of the cancer and other

parameters. Conventional pharmaceutical carriers, diluents or conventional additives can be present.

[0017] The dosage can be freely selected as a function of the clinical picture and the condition of the patient.

[0018] The invention finally comprises a pharmaceutical composition or a medicament for the treatment of cancer, which contains at least one active agent for influencing, particularly inhibiting the expression of matrix-metalloproteases in eukaryotic cells. Relating to the individual features of such composition or medicament, reference is made to the corresponding description text above.

[0019] The described features and further features of the invention can be gathered from the following description of preferred embodiments in conjunction with the subclaims. The individual features can be implemented separately or in the form of subcombinations.

MATERIALS AND METHODS

[0020] Tissue Culture and Materials. UM-SCC-1 cells (known to a skilled person and obtainable from Dr. Thomas Carey, University of Michigan, Ann Arbor, MI), Hla82 (known to a skilled person and obtainable from Dr. Hans Peter Zenner, University of Tübingen, Germany) and NIH 3T3 cells (maintained by nearly every cell biology laboratory and also obtainable from Dr. Hans Peter Zenner, see above), were maintained in McCoy's 5A culture medium supplemented with 10% fetal bovine serum (FBS, Gibco Life Technologies, Karlsruhe, Germany). For the collection of conditioned medium for zymography and Western blotting, 80% confluent UM-SCC-1, Hla82 and NIH 3T3 cells respectively were incubated in serum-free medium (McCoy's 5A medium, components known to a skilled person and available from Gibco Life Technologies, Karlsruhe, Germany) for 48 hours, when indicated with or without SB 203580 (Calbiochem, San Diego, CA) or carrier (DMSO) added at the same time. In the following "serum-free medium" will also be abbreviated as "SFM". The culture medium was collected and proliferation determined after incubating cells in 0.2-mg/ml MTT-vital stain and reading aliquots of DMSO dissolved formazan crystals by spectrophotometry at 570 nm. Growth curves were constructed as described (25) using various amounts of SB 203580 added at the same time after allowing 12 hours for cell attachment.

[0021] Zymography. Zymography was performed exactly as described (20, 25) using SDS-PAGE gel containing 0.1% (wt/vol) gelatin to assay for MMP-9. MMP-dependent proteolyses was detected as white zones in a dark field.

[0022] Western Blotting. For the detection of MMP-9 in conditioned medium, medium from equal numbers of cells was denatured in the absence of reducing agent, proteins resolved by SDS-PAGE and then transferred to a nitrocellulose filter. The filter was blocked with 3% BSA and incubated with a mouse monoclonal antibody

to matrix metalloprotease (#1M37L Oncogene Research Products, Calbiochem, Cambridge, MA). Subsequently, the blot was incubated with horse radish peroxidase-conjugated anti-rabbit IgG and immunoreactive bands visualized by ECL (Enhanced Chemiluminescence), a commercially available immunoblotting detecting system as described by the manufacturer (Amersham Life Science, Arlington Heights, IL). p38 α -pha and SAPK3 protein was detected using monoclonal antibodies equally recognizing phospho- and dephospho-p38 (sc-535-G and sc-6023, Santa Cruz, Santa Cruz, CA). Briefly cells were extracted in RIPA-buffer containing PMSF (100mg/ml) and sodium orthovanadate (1 mM). SDS-PAGE was used to resolve proteins extracted under denaturing conditions. The filter was blocked with 3% BSA and subsequently incubated with the primary antibody over night. To visualize immunoreactive bands the ECL-system was again used.

[0023] In-gel Kinase Assay for p38 α activity and SAPK3 activity assay. Kinase assays for p38 α activity were performed as described (20). Briefly, cells were extracted with buffer A [1% NP40 (octylphenoxy polyethoxy ethanol), 25 mM Tris-HCl (pH 7.4), 25 mM NaCl, 1 mM sodium vanadate, 10 mM NaF, 10 nM sodium pyrophosphate, 10 nM okadaic acid, 0.5 mM EGTA, and 1 mM phenylmethylsulfonyl fluoride]. Extracted protein was incubated with 2 μ g of the anti-p38 α antibody immunoreactive with human and mouse p38 α (sc-535-G, Santa Cruz, Santa Cruz, CA) and Protein-A agarose beads (2 mg) for immunoprecipitation. The beads were washed with buffer A and resuspended in 2X sample buffer, and the immune complexes were electrophoresed in a polyacrylamide gel containing myelin basic protein. The gel was treated sequentially with buffers containing 20% 2-propanol, 5 mM 2-mercaptoethanol, 6 M guanidine HCl and 0.04% Tween 40-5 mM 2-mercaptoethanol. The gel was then incubated at 25°C for 1 h with 10 μ M ATP and 25 μ Ci of [³²P]ATP in a buffer containing 2 mM dithiothreitol-0.1 mM EGTA-5 mM MgCl₂, washed in a solution containing 5% trichloroacetic acid and 1% sodium pyrophosphate, dried, and autoradiographed. For SAPK3 activity cells were extracted in a buffer A, extracted protein incubated with 2 μ g of the anti-SAPK3-antibody immunoreactive with human and mouse SAPK3 (06-603, Upstate Biotechnology, Lake Placid, NY, USA) and protein G agarose beads. Beads were washed in buffer A and kinase buffer (50mM HEPES, 0.1 mM EDTA, 0.0001% Brij35, 0.0001% β -mercaptoethanol, 150mM NaCl, 0.1mg/ml bovine serum albumin) and subjected to kinase reaction with 1 μ g ATF2 (sc-4007, Santa Cruz, Santa Cruz, CA, USA) as the substrate in 40 μ l of reaction buffer (kinase buffer, 0.3mM ATP, 0.4M MgCl₂) at 30°C for 30 min. The reaction was terminated by adding 2X reducing sample buffer and heating to 100°C for 5 min. The beads were removed by centrifugation. The supernatant was subjected to immunoblotting as described above with an anti-phospho-ATF2-antibody. Immunoreactive bands were

visualized using the ECL-system.

[0024] In Vitro invasion assays. Invasion assays were performed as described (20, 25) using filters with 8 μ m pore size coated with 1/3 diluted Matrigel®/SFM (Becton Dickinson, Bedford, MA). Cells were plated out in SFM containing SB 203580 or DMSO, the carrier of SB 203580, at similar concentrations. For experiments utilizing a mouse monoclonal MMP-9 Antibody (#IM09L, Oncogene Research Products, Cambridge, MA) (0.5, 1, and 10 μ g/ml) cells were either plated out in SFM plus antibody of SFM plus similar amounts of preimmune serum. The amount of invasion was determined on the basis of the MTT activity on the lower side of the filter as a percentage of the total activity in the chamber.

[0025] Transient transfections with subsequent CAT-ELISA. Transient transfections were carried out using Lipofectamin® (GIBCO, Life Technologies, Karlsruhe, Germany) for transient transfection as described by the manufacturer. UM-SCC-1 and NIH 3T3 cells were co-transfected at 70% confluence with a CAT reporter construct containing 670 bp of the MMP9 wild-type promoter including the transcriptional start site or the promoterless CAT construct (SV₀) (3 μ g) along with a pCDNA3-MKK-6 or -MKK-3 constitutive active mutant (0.03-3 μ g) as described (26), or dominant negative p38alpha, beta, SAPK3, SAPK4 or MKK-6 mutants with a one- or twofold molar excess to the promoter construct (kindly provided by Dr. J. Han, Scripps Research Institute, La Jolla, CA). The transfected DNA-amount was equalized in each sample using mock control vector (pCDNA3). CAT ELISA, measuring CAT protein expression, was performed according to the manufacturer (Roche Diagnostics, Mannheim, Germany).

[0026] In the drawings it is shown:

Figure 1: Influence of SB 203580 on MMP-9 expression (A), in-vitro invasion (B) and growth (C) of UM-SCC-1 cells.

Figure 2: Requirement of MMP-9 secretion for in-vitro invasion in different cell lines (A), expression of MMP-9 in different cell lines (B) and percentage of in-vitro invasion after incubation with anti-MMP-9 antibody (C).

Figure 3: Influencing of MMP-9 promoter activity after treatment with dominant negative p38 isoform proteins (A), and the expression of p38alpha and p38gamma in two different cell lines (B-E).

Figure 4: Expression of MMP-9 in two different cell lines (A), influencing of MMP-9 promoter activity after treatment with a kinase deficient MKK6 (B) and constitutive active MKK6 and MKK3 (C) mutants.

Experiment 1

[0027] UM-SCC-1 cells were plated out in McCoy's 5A

culture medium supplemented with 10 % fetal bovine serum (FBS, Gibco Life Technologies, Karlsruhe, Germany) and replenished the following day with serum-free medium containing SB 203580 (10 μ M, Calbiochem, San Diego, CA) or carrier (dimethylsulfoxide DMSO, 0.01 %). After 48 hours, the condition medium was harvested and proliferation rates were assayed with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). Aliquots of condition medium, normalized for proliferation differences, were subjected to immunoblotting using a monoclonal anti-MMP-9 antibody. Subsequently, the blot was incubated with horse radish peroxidase-conjugated anti-rabbit IgG and immunoreactive bands visualized by ECL as described by the manufacturer (Amersham, Arlington Heights, IL). A reduction of protein expression of 70 % was noted according to densitometric measurement. The data are typical of triplicate experiments.

[0028] The results of experiment 1 are represented in Figure 1.

[0029] Figure 1A shows that the squamous cell carcinoma cell line UM-SCC-1 which constitutively produces large amounts of MMP-9 and displays an in-vitro and in-vivo invasive phenotype is influenced by treatment with the imidazol derivative SB 203580. SB 203580 reduced MMP-9 protein expression by approximately 70% at concentrations of 10 μ M, as evidenced by immunoblotting analysis.

[0030] In Figure 1B, UM-SCC-1 cells were plated out on filters precoated with Matrigel® in serum-free medium and incubated with various amounts of SB 203580 for 60 hours to assay for in-vitro invasion. The concentration of the carrier (DMSO) was maintained at 0.1%. Invasion is expressed as the percentage of cells invading through the Matrigel®. Invasion upon treatment with varying concentrations of SB 203580 is expressed as average percentage \pm S.E. and represents 3 dishes in each group. The data are typical of triplicate experiments. Figure 1B shows that there is a dose dependent reduction of in-vitro invasion by 43 \pm 9% and 69 \pm 8% using concentrations of 5 μ M and 10 μ M, respectively.

[0031] Figure 1C shows that the exposure of UM-SCC-1 cells to 5 μ M and 10 μ M of the p38 inhibitor for up to 5 days does not affect cell growth excluding antimetabolic effects of the compound to be responsible for the inhibitory effect on in-vitro invasion. p38 isoforms differ with respect to their sensitivity towards SB 203580. The reported IC₅₀ is 0.1 μ M for p38alpha but 5-10 μ M for p38beta. p38gamma and p38delta are not inhibited by the imidazol derivative (27). Hence, the concentration of SB 203580 required to reduce MMP-9 expression and in-vitro invasion of UM-SCC-1 cells closely matches the IC₅₀ of p38beta. In this experiment the cells were grown in culture medium containing 10% FBS for 5 days with various amounts of SB 203580. Number of viable cells was determined with 0.2 mg/ml MTT-vital stain and consecutive reading of DMSO-dissolved formazan crystals by spectrophotometry at 570 nm on the

indicated days. The data points are typical of triplicate experiments.

[0032] Thus, experiment 1 and the associated Figure 1 show that the p38 SAPK inhibitor SB 203580 reduces high-level expression of MMP-9 and in-vitro invasion of UM-SCC-1 cells without having any effect on cell growth.

Experiment 2

[0033] In this experiment different cell lines were plated out on filters precoated with Matrigel® in serum-free medium and incubated. Invasion is expressed as the average percentage \pm S.E. and represents 3 dishes in each group. The data are typical of triplicate experiments.

[0034] To address the question if MMP-9 might be required for in-vitro invasion of UM-SCC-1 cells, first expression levels of three different cell lines (UM-SCC-1, NIH3T3, Hlac82) were correlated with their in-vitro invasive behavior. Figure 2A shows that the amount of the MMP-9 in the conditioned medium closely paralleled the invasiveness of the cell lines. While UM-SCC-1 cells produce the most protease and exhibit the most invasive phenotype, NIH3T3 cells, which do not secrete any detectable MMP-9, were by far less invasive on Matrigel® coated filters. Interestingly, there was no correlation between MMP-2 secretion and invasiveness of the tested cell lines. This might be due to the requirement of the presence of distinct membrane type matrix-metalloproteases (MT-MMP's) for the activation of MMP-2 (21), which may not be expressed on NIH3T3 cells.

[0035] According to Figure 2B, the different cell lines were changed to serum-free medium and cultured for 48 hours. Condition medium was harvested and cell numbers were determined using MTT. Aliquots of conditioned medium corrected for differences in cell numbers were assayed for MMP-9 activity by zymography as described (20, 25) and as is known by those skilled in the art. The data are typical of triplicate experiments. Only the cell line that expresses the highest amount of MMP-9 shows a clear band in zymography.

[0036] To finally demonstrate the requirement for MMP-9 activity for the in-vitro invasive phenotype of UM-SCC-1 cells, in Figure 2C UM-SCC-1 cells were plated out on filters precoated with Matrigel® in serum-free medium and incubated with various amounts of an anti-MMP-9 antibody (0.5, 1, 10 μ g/ml) or equivalent amounts of preimmun serum provided by the manufacturer for 60 hours. Invasion is expressed as the percentage of cells invading through Matrigel®. Invasion upon treatment with varying concentrations of the antibody recognizing the active and latent form of MMP-9 or pre-immune serum provided by the manufacturer is expressed as average percentage \pm S.E. and represents 3 dishes in each group. The data are typical of triplicate experiments. Figure 2C shows that there is a dose dependent reduction of in-vitro invasion with increasing

concentrations of the antibody.

[0037] Thus, experiment 2 and the associated Figure 2 show that there is a requirement for MMP-9 secretion into the conditioned medium of UM-SCC-1 cells for in-vitro invasion of the cell line. Therefore it can be concluded, that SB 203580 inhibits in-vitro invasion of UM-SCC-1 cells by reducing MMP-9 expression via a p38 signaling pathway.

Experiment 3

[0038] As MMP-9 expression is almost exclusively regulated at the promoter level (28, 29), and to further characterize the role of different p38 isoforms in the regulation of MMP-9 expression, UM-SCC-1 cells were transiently transfected using Lipofectamin® (Gibco Life Technologies, Karlsruhe, Germany) as described by the manufacturer and a chloramphenicol acetyl transferase (CAT) reporter driven by the wild type MMP-9 promoter or the promoterless CAT construct (SV₀) and the indicated amount (where 2 is a twofold molar excess of the effector plasmid relative to the reporter construct) of an expression vector including a dominant negative p38alpha, p38beta, p38gamma and p38delta or the empty vector (pCDNA3). Differences in transfected DNA-amount were normalized with empty vector. Cell extracts, normalized for differences in protein amount, were assayed for CAT expression using CAT-ELISA according to the manufacturer (Roche Diagnostics, Mannheim, Germany). Data are expressed as average percent of control \pm S.E. and represent 2 dishes in each group, performed in 3 separate experiments. The kinase deficient mutants were created by substituting the threonine by alanine and the tyrosine by phenylalanine in the typical TGY sequence of the p38 kinases and all resultant cDNA's cloned into the mammalian expression vector pCDNA3 by standard molecular biology techniques as known by those skilled in the art.

[0039] According to Figure 3A, a SB 203580 sensitive isoform mutant, p38beta, was found to repress the activity of the MMP-9 promoter driven CAT reporter by 62 \pm 20% at a twofold molar excess, while, quite in contrast, the p38alpha mutant only reduced MMP-9 promoter activity by 21 \pm 20%. The p38delta mutant inhibited the MMP-9 promoter by 55 \pm 9%. Transfection with the p38gamma mutant virtually silenced the MMP-9 promoter, i. e. promoter activity was repressed by 99.9 \pm 0.5%. No significant CAT expression was noted upon transfection of the promoterless CAT construct.

[0040] Figure 3A shows that p38gamma besides p38beta and p38delta, but not p38alpha, dominant negative expression constructs reduce MMP-9 promoter activity. This experiment further supports the involvement of p38beta rather than p38alpha in the constitutive activation of the MMP-9 promoter and in addition, they strongly suggest a role for p38delta and most importantly p38gamma in the constitutive activation of the MMP-9 promoter.

[0041] In Figure 3B-E UM-SCC-1 and NIH3T3 cells were maintained in culture medium containing 10% FBS. Protein extracts (equal protein) and in-gel kinase assay were prepared as indicated above and subjected to either immunoblotting using a polyclonal anti-p38alpha- or SAPK3- antibody (B) and (D), or in-gel kinase assay using MBP as a substrate (C), or immunokinase reaction using recombinant ATF2 as a substrate (E). The data are typical of triplicate experiments. By these experiments it was excluded that the modest reduction of MMP-9 promoter activity observed after inhibition of p38alpha by a kinases deficient mutant could also be due to missing expression and/or activity of the kinase. For this, UM-SCC-1 cells and NIH3T3 cells (negative control) were assayed for activity and expression of p38alpha. Expression and activity of p38gamma was also analyzed by immunoprecipitation with a polyclonal SAPK3-antibody and subsequent kinase reaction in a similar experiment.

[0042] As can be gathered from Figure 3 B-E presence of both proteins, p38alpha and p38gamma, was noted in both cell lines (Figure 3B and C). However, enzyme activity of both p38 isoforms was found to be high in UM-SCC-1 cells as opposed to undetectable in NIH3T3 cells. Hence, p38alpha and p38gamma are present and constitutively active in UM-SCC-1 cells.

Experiment 4

[0043] Here UM-SCC-1 and NIH3T3 cells were changed to serum-free medium and cultured for 48 hours. Condition medium was harvested and cell numbers were determined using MTT. Aliquots of conditioned medium corrected for differences in cell number were assayed for MMP-9 activity by zymography. The data are typical of triplicate experiments.

[0044] Figure 4A shows that UM-SCC-1 cells, but not NIH3T3 cells, express the matrix-metalloprotease 9 (MMP-9).

[0045] As MKK6 protein kinase broadly activates p38 isoforms (in contrast to MKK3, which acts as rather specific activator of the p38alpha and SAPK4/p38delta isoforms) (26, 30), and in order to determine the role of MKK6 in the regulation of MMP-9, in Figure 4B UM-SCC-1 cells were transiently transfected using a CAT reporter driven by the wild type MMP-9 promoter or promoterless CAT construct (SV₀) and the indicated amount (where 2 is a twofold molar excess of the effector plasmid relative to the reporter construct) of an expression vector encoding a kinase dead MKK6 mutant. The kinase dead phenotype was created by substituting serine¹⁵¹ and threonine¹⁵⁵ with alanine according to the above noted publication (26). A strong reduction of MMP-9 promoter activity by 99 +/- 0.5% was observed. These data demonstrate that a MKK6 kinase deficient mutant represses MMP-9 promoter activity in UM-SCC-1 cells and that MKK6 is an upstream regulator of MMP-9, which likely signals through p38 isoforms.

[0046] In order to further characterize the role of MKK6 in the regulation of the MMP-9 promoter, the effect of constitutive activation of MKK6 kinase was examined. In Figure 4C NIH3T3 cells were transiently transfected using a CAT reporter driven by the wild type MMP-9 promoter or the promoterless CAT construct (SV₀) and the indicated amount (where 2 is a twofold molar excess of the effector plasmid relative to the reporter construct) of an expression vector encoding a constitutively activated MKK6 and MKK3 protein or the empty vector. Differences in transfected DNA-amount were normalized with empty vector. Cell extracts, normalized for differences in protein amount, were assayed for CAT expression using CAT-ELISA. Data are expressed as average percent of control +/-S.E. and represent 2 dishes in each group, performed in 3 separate experiments. The constitutive activation of MKK6 was achieved by substituting serine¹⁵¹ and threonine¹⁵⁵ by glutamic acid according to the publication of J. Hahn et al (26). To avoid interfering activation of the promoter by endogenous stimulators, NIH3T3 cells, which do not express endogenous MMP-9 (Figure 4A) were utilized. A five fold activation of the MMP-9 promoter was noted after co-transfection with a CAT reporter and the MKK6 mutant at a one fold molar excess. The same experiment was repeated with a similarly created MKK3 mutant. At a similar molar excess, only a 2.8 fold induction of the promoter was observed.

[0047] Figure 4C demonstrates that there is a rather unspecific activation of all p38 isoforms (including p38gamma) by MKK6, while MKK3 more narrowly targets p38alpha and p38delta. These results support the role for p38gamma in the regulation of MMP-9.

[0048] All these results clearly demonstrate that according to the present invention cancer, preferably invasiveness of cancer metastasis will be positively influenced by administration of an active agent which influences, particularly inhibits downstream regulators of the MMP-9 signal transduction pathway.

Literature

[0049]

1. Simon, C., M.J. Hicks, A.J. Nemecek, R. Meetha, B.W. O'Malley, H. Goepfert, C.M. Flaitz, and D. Boyd. 1999. PD 098059, an inhibitor of ERK1 activation, attenuates the in vivo invasiveness of head and neck squamous cell carcinoma. *Br J Cancer* 80: 1412-1419
2. Ikebe, T., M. Shinohara, H. Takeuchi, M. Beppu, S. Kurahara, S. Nakamura, and K. Shirasuna. 1999. Gelatinolytic activity of matrix metalloproteinase in tumor tissues correlates with the invasiveness of oral cancer. *Clin Exp Metastasis* 17:(4) 315-323
3. Denhardt, D.T. 1996. Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: the potential for

- multiplex signaling. *Biochem J* 318: 729-747
4. Hunter, T. 1997. Oncoprotein networks. *Cell* 88: (3) 333-346
 5. Lengyel, E., R. Gum, E. Stepp, J. Juarez, H. Wang, and D. Boyd. 1996. Regulation of urokinase-type plasminogen activator expression by an ERK1-dependent signaling pathway in a squamous cell carcinoma cell line. *J Cell Biochem.* 61:(3) 430-443
 10. Oka, H., Y. Chatani, R. Hoshino, O. Ogawa, Y. Kakehi, T. Terachi, Y. Okada, M. Kawaichi, M. Kohno, and O. Yoshida. 1995. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. *Cancer Res* 55:(18) 4182-4187
 15. Kim, S.C., J.S. Hahn, Y.H. Min, N.C. Yoo, Y.W. Ko, and W.J. Lee. 1999. Constitutive activation of extracellular signal-regulated kinase in human acute leukemias: combined role of activation of MEK, hyperexpression of extracellular signal-regulated kinase, and downregulation of a phosphatase, PAC1. *Blood* 93:(11) 3893-3899
 8. Garrington, T.P. and G.L. Johnson. 1999. Organisation and regulation of mitogen-activated protein kinase signaling pathways. *Curr Opin Cell Biol* 11: (2) 211-218
 9. Lee, J.C., J.T. Laydon, P.C. McDonnell, T.F. Gallagher, S. Kumar, D. Green, D. McNulty, M.J. Blumenthal, J.R. Heys, S.W. Landvatter, J.E. Strickler, M.M. McLaughlin, I.R. Siemens, S.M. Fisher, G.P. Livi, J.R. White, J.L. Adams, and P.R. Young. 1994. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. *Nature* 372: 739-746
 10. Jiang, Y., C. Chen, Z. Li, W. Guo, J.A. Gegner, S. Lin, and J. Han. 1996. Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta). *J Biol Chem* 271:(30) 17920-17926
 11. Li, Z., Y. Jiang, R.J. Ulevitch, and J. Han. 1996. The primary structure of p38gamma: A new member of p38 group of MAP kinases. *Biochem Biophys Res Commun* 228:(2) 334-340
 12. Wang, X.S., K. Diener, C.L. Manthey, S. Wang, B. Rosenzweig, J. Bray, J. Delaney, C.N. Cole, P. Chan-Hui, N. Mantlo, H.S. Lichenstein, M. Zukowski, and Z. Yao. 1997. Molecular cloning and characterization of a novel p38 mitogen-activated protein kinase. *J Biol Chem* 272:(38) 23668-23674
 13. Lechner, C., M.A. Zahalka, J.F. Giot, N.P. Moller, and A. Ullrich. 1996. ERK6, a mitogen-activated protein kinase involved in C2C12 myoblast differentiation. *Proc Natl Acad Sci USA* 93:(9) 4355-4359
 14. Conrad, P.W., R.T. Rust, J. Han, E.E. Millhorn, and D. Beitner-Johnson. 1999. Selective activation of p38alpha and p38gamma by hypoxia. *J Biol Chem* 274:(33) 23570-23576
 15. Mertens, S., M. Craxton, and M. Goedert. 1996. SAP kinase-3, a new member of the family of mammalian stress-activated protein kinases. *FEBS Letters* 383:(3) 273-276
 16. Fang, F.M., S.W. Leung, C.C. Huang, Y.T. Liu, C.J. Wang, H.C. Chen, L.M. Sun, and D.T. Huang. 1997. Combined-modality therapy for squamous carcinoma of the buccal mucosa: treatment results and prognostic factors. *Head Neck* 19(6) 506-512
 17. Kugler, A. 1999. Matrix metalloproteinases and their inhibitors. *Anticancer Res* 19:(2C) 1589-1592
 18. Murray, G.I., M.E. Duncan, E. Arbuckle, W.T. Melvin, and J.E. Fothergill. 1998. Matrix metalloproteinases and their inhibitors in gastric cancer. *Gut* 43:(6) 791-797
 19. Denhardt, D.T., B. Feng, D.R. Edwards, E.T. Cocuzzi, and U.M. Malyankar. 1993. Tissue inhibitor of metalloproteinases (TIMP, aka EPA); structure, control of expression and biological functions. *Pharmacol Ther* 59:(3) 329-341
 20. Simon, C., H. Goepfert, and D. Boyd. 1998. Inhibition of the p38 mitogen-activated protein kinase by SB 203580 blocks PMA-induced Mr 92,000 type collagenase secretion and in vitro invasion. *Cancer Res* 58: 1135-1139
 21. Price, J.T., M.T. Bonovich, and E.C. Kohn. 1997. The biochemistry of cancer dissemination. *Critical Reviews in Biochemistry and Molecular Biology* 32: (3) 175-253
 22. Fukami, Y., A.A. Tokmakov, K. Konaka, and K. Sato. 1999. Peptide inhibitors of the mitogen-activated protein kinase pathway: a structure-mimetic peptide corresponding to the conserved inter-DFG-APE region in the kinase domain. *Pharmacol Ther* 82:(2-3) 399-407
 23. Lee, J.C., S. Kassis, S. Kumar, A. Badger, and J.L. Adams. (1999). p38 mitogen-activated protein kinase inhibitors-mechanisms and therapeutic potentials. *Pharmacol Ther* 82:(2-3) 389-397
 24. Fabbro, D., E. Buchdunger, J. Wood, J. Mestan, F. Hofman, S. Ferrari, H. Mett, T. O'Reilly, and T. Meyer. (1999). Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent. *Pharmacol Ther* 82:(2-3) 293-301
 25. Simon, C., J. Juarez, G.L. Nicolson, and D. Boyd. 1996. Effect of PD 098059, a specific inhibitor of mitogen-activated protein kinase kinase, on urokinase expression and in vitro invasion. *Cancer Res* 56: 5369-5374
 26. Han, J., J.D. Lee, Y. Jiang, Z. Li, L. Feng, and R.J. Ulevitch. 1996. Characterization of the structure and function of a novel MAP kinase kinase (MKK6). *J Biol Chem* 271:(6) 2886-2891
 27. Kumar, S., P.C. McDonnell, R.J. Gum, A.T. Hand, J.C. Lee, and P.R. Young. 1997. Novel homologues of CSBP/p38 MAP kinase: Activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles. *Biochem Biophys Res Commun* 235:(3) 533-538

28. Gum, R., H. Wang, E. Lengyel, J. Juarez, and D. Boyd. 1997. Regulation of 92 kDa type 4 collagenase expression by the jun aminoterminal kinase- and the extracellular signal-regulated kinase-dependent signaling cascades. *Oncogene* 14: 1481-1493

29. Gum, R., E. Lengyel, J. Juarez, J.H. Chen, H. Sato, M. Seiki, and D. Boyd. 1996. Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase-1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. *J Biol Chem* 271:(18) 10672-10680

30. Cuenda, A., P. Cohen, V. Buee-Scherrer, and M. Goedert. 1996. Activation of stress-activated protein kinase-3 (SAPK3) by cytokines and cellular stresses is mediated via SAPKK3 (MKK6): comparison of the specificities of SAPK3 and SAPK2 (RK/p38). *EMBO J* 16:(2) 295-305

Claims

1. Use of an active agent for influencing, particularly inhibiting the expression of matrix-metalloproteases in eukaryotic cells, for the preparation of a medicament or a pharmaceutical composition for the treatment of cancer.
2. Method for the treatment of cancer, **characterized in that** eukaryotic cells are treated by an active agent which influences, particularly inhibits the expression of matrix-metalloproteases.
3. Use or method according to claim 1 or 2, **characterized in that** said matrix-metalloprotease is the matrix-metalloprotease-9 (MMP-9).
4. Use or method according to one of the preceding claims, **characterized in that** said active agent is targeted against at least one member of the matrix-metalloprotease signal transduction pathway.
5. Use or method according to claim 4, **characterized in that** said member is a member of the p38 protein family.
6. Use or method according to claim 5, **characterized in that** said p38 protein is the p38beta protein.
7. Use or method according to claim 5, **characterized in that** said p38 protein is the p38gamma (SAPK3 or ERK6) protein.
8. Use or method according to claim 4, **characterized in that** said member is a member of the mitogen-activated kinase kinase family.
9. Use or method according to claim 8, **characterized in that** said mitogen-activated kinase kinase is the mitogen-activated kinase kinase 6 (MKK6) or the mitogen-activated kinase kinase 3 (MKK3).
10. Use or method according to one of the preceding claims, **characterized in that** said active agent is targeted against activators, regulators and/or biological precursors of the matrix-metalloprotease signal transduction pathway.
11. Use or method according to one of the preceding claims, **characterized in that** said active agent is a small molecular compound, preferably a small molecular compound with a molecular weight (MW) < 1000.
12. Use or method according to claim 11, **characterized in that** the small molecular compound is an imidazole derivative, wherein preferably said imidazole derivative is SB 203580 or SB 202190.
13. Use or method according to one of the preceding claims, **characterized in that** said active agent is a polynucleotide encoding a peptide, preferably a polypeptide, which influences, preferably inhibits the expression of matrix-metalloproteases.
14. Use or method according to one of the preceding claims, **characterized in that** said cancer is of the invasive phenotype.
15. Use or method according to one of the preceding claims, **characterized in that** said cancer is;
 - a) a squamous epithelial carcinoma, preferably a squamous epithelial carcinoma of the head, neck, skin or stomach, or
 - b) a colon-, breast- or hepatocellular carcinoma, or
 - c) a fibrosarcoma of the stomach.
16. Pharmaceutical composition, comprising a compatible quantity of at least one active agent, wherein said active agent is influencing, preferably inhibiting the expression of matrix-metalloproteases in eukaryotic cells, and optionally further comprising a pharmaceutically acceptable carrier.
17. Pharmaceutical composition according to claim 16, further **characterized by** an active agent as defined in one of the claims 4 to 13.

Fig.1






Fig.2




BEST AVAILABLE COPY

Fig.3



BEST AVAILABLE COPY

Fig.4



Application Number

which under Rule 45 of the European Patent Convention shall be considered, for the purposes of subsequent proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim
X	<p>WO 99 58128 A (EYERS PATRICK ALEXANDER; MEDICAL RES COUNCIL (GB); COHEN PHILIP (G) 18 November 1999 (1999-11-18))</p> <p>* abstract *</p> <p>* page 19, line 25 - page 20, line 5 *</p> <p>* page 20, line 26 - page 21, line 4 *</p> <p>* page 23, line 15 - line 22 *</p> <p>* page 29, line 19 - line 28 *</p> <p>* page 30, line 16 - line 26 *</p> <p>* page 33, line 1 - line 8 *</p> <p>* figures 5,6 *</p> <p>* page 36, line 11 - line 26 *</p> <p>* page 44, line 20 - page 45, line 1 *</p> <p>* claims 22,26,28 *</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/-</p>	<p>1-12, 14-17</p>
		<p>CLASSIFICATION OF THE APPLICATION (Int.Cl.7)</p> <p>A61K31/00 A61K31/4439 A61P35/00</p>
		<p>TECHNICAL FIELDS SEARCHED (Int.Cl.7)</p> <p>A61K</p>
INCOMPLETE SEARCH		
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p>see sheet C</p>		
Place of search	Date of completion of the search	Examiner
THE HAGUE	18 December 2000	Cielen, E
CATEGORY OF CITED DOCUMENTS		
<p>X : particularly relevant if taken alone</p> <p>Y : particularly relevant if combined with another document of the same category</p> <p>A : technological background</p> <p>O : non-written disclosure</p> <p>P : intermediate document</p> <p>T : theory or principle underlying the invention</p> <p>E : earlier patent document, but published on, or after the filing date</p> <p>D : document cited in the application</p> <p>L : document cited for other reasons</p> <p>-----</p> <p>a : member of the same patent family, corresponding document</p>		

European Patent
OfficeINCOMPLETE SEARCH
SHEET CApplication Number
EP 00 11 4909

Although claims 2-15 are directed to a method of treatment of the human/animal body (Article 52(4) EPC), the search has been carried out and based on the alleged effects of the compound/composition.

Claim(s) searched completely:

12

Claim(s) searched incompletely:

1-11,13-17

Reason for the limitation of the search:

Present claims 1-11,13-17 relate to a therapeutic use of, a method of using and a composition comprising an active agent defined by reference to a desirable characteristic or property, namely "for influencing, particularly inhibiting the expression of matrix-metalloproteases". The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 84 EPC and/or disclosure within the meaning of Article 83 EPC for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 84 EPC). An attempt is made to define the compounds by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

Moreover, claims 4, 10, 11 and 13 refer to compounds which actually are not well defined. The use of the definition "an active agent targeted against at least one member of the matrix-metalloprotease signal transduction pathway", "an active agent targeted against activators, regulators and/or biological precursors of the matrix-metalloprotease signal transduction pathway", "a small molecular compound" and "a polynucleotide" in the present context is considered to lead to a lack of clarity within the meaning of Article 84 EPC. The lack of clarity is such as to render a meaningful complete search impossible.

Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds specifically mentioned in claim 12, i.e. SB 203580 and SB 202190.



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 00 11 4909

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
D,X	<p>SIMON CHRISTIAN ET AL: "Inhibition of the p38 mitogen-activated protein kinase by SB 203580 blocks PMA-induced Mr 92,000 type IV collagenase secretion and in vitro invasion." CANCER RESEARCH, vol. 58, no. 6, 15 March 1998 (1998-03-15), pages 1135-1139, XP000971378 ISSN: 0008-5472 * abstract * * page 1135, column 2, paragraph 2 * * page 1137, column 2, paragraph 1 - page 1138, column 1, paragraph 1 * * page 1138, column 1, paragraph 4 - column 2, paragraph 1 * * page 1139, column 1, paragraphs 2,5 * ---</p>	1-12,14,15	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
X	<p>CHEN W ET AL: "Activation of p38 MAP kinase and ERK are required for ultraviolet-B induced c-fos gene expression in human keratinocytes." ONCOGENE, (1999 DEC 9) 18 (52) 7469-76. , XP000974811 * abstract * * page 7474, column 1, paragraph 2 - column 2, paragraph 2 * --- -/--</p>	1,2,4-12,15	

EPO FORM 1503 03.02 (P04C10)



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 00 11 4909

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	<p>KAHARI VELI-MATTI ET AL: "Matrix metalloproteinases and their inhibitors in tumour growth and invasion." ANNALS OF MEDICINE, vol. 31, no. 1, February 1999 (1999-02), pages 34-45, XP000971534 ISSN: 0785-3890 * abstract * * page 39, column 2, paragraph 2 - page 40, column 1, paragraph 2 * * page 40, column 1, paragraph 5 - column 2, paragraph 2 * * table 1 * * page 41, column 2, paragraph 1 *</p>	1-14,16,17	
X	<p>RASMUSSEN H S ET AL: "MATRIX METALLOPROTEINASE INHIBITION AS A NOVEL ANTICANCER STRATEGY: A REVIEW WITH SPECIAL FOCUS ON BATIMASTAT AND MARIMASTAT" PHARMACOLOGY AND THERAPEUTICS, ELSEVIER, GB, vol. 75, no. 1, 1997, pages 69-75, XP000925450 ISSN: 0163-7258 * abstract * * page 69, column 2, paragraph 1 * * page 70, column 1, paragraph 2 - column 2, paragraph 2 * * page 71, column 1, paragraph 1 - column 2, paragraph 1 * * page 72, column 1, paragraph 3 - paragraph 4 * * page 73, column 1, paragraph 3 - column 2, paragraph 1 * * page 74, column 1, paragraph 2 *</p>	1-4,10,11,14-17	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
	-/--		



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 00 11 4909

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	ALBINI A ET AL: "INHIBITION OF INVASION, GELATINASE ACTIVITY, TUMOR TAKE AND METASTASIS OF MALIGNANT CELLS BY N-ACETYLCYSTEINE" INTERNATIONAL JOURNAL OF CANCER,US,NEW YORK, NY, vol. 61, no. 1, 29 March 1995 (1995-03-29), pages 121-129, XP000675336 ISSN: 0020-7136 * abstract * * page 121, column 2, paragraph 3 - page 122, column 1, paragraph 1 * * page 126, column 1, paragraph 2 - column 2, paragraph 2 * * page 128, column 1, paragraph 3 - column 2, paragraph 1 *	1-11,14,16,17	
D,X	--- SIMON C ET AL: "PD 098059, an inhibitor of ERK1 activation, attenuates the in vivo invasiveness of head and neck squamous cell carcinoma." BRITISH JOURNAL OF CANCER, vol. 80, no. 9, July 1999 (1999-07), pages 1412-1419, XP000974433 ISSN: 0007-0920 * abstract * * page 1413, column 1, paragraph 1 - paragraph 2 * * page 1413, column 2, paragraph 3 * * page 1417, column 1, paragraph 1 - page 1418, column 1, paragraph 2 * --- -/--	1-11,14-17	TECHNICAL FIELDS SEARCHED (Int.Cl.7)

EPO FORM 1503 02.92 (P04C10)



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 00 11 4909

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	EP 0 623 676 A (AMGEN INC ;LOS ANGELES CHILDRENS HOSPITAL (US)) 9 November 1994 (1994-11-09) * abstract * * page 3, line 16 - line 22 * * page 4, line 19 - line 28 * * page 6, line 40 - line 47 * * table 2 * * page 30, line 7 - line 31 * * examples 12,13 * * claims 1,2,5,15,18,32,33,35 * ---	1-4,10, 13,16,17	
X	DECLERCK Y A ET AL: "INHIBITION OF INVASION AND METASTASIS IN CELLS TRANSFECTED WITH AN INHIBITOR OF METALLOPROTEINASES" CANCER RESEARCH,US,AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, vol. 52, 1 February 1992 (1992-02-01), pages 701-708, XP002010519 ISSN: 0008-5472 * abstract * * page 701, column 2, paragraph 3 * * page 704, column 2, paragraph 3 - page 705, column 1, paragraph 1 * * page 705, column 2, paragraph 2 - page 706, column 1, paragraph 1 * * page 707, column 1, paragraph 1 - column 2, paragraph 1 * --- -/--	1,2,4, 10,13,14	TECHNICAL FIELDS SEARCHED (Int.Cl.7)



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 00 11 4909

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	WO 99 42443 A (NOVARTIS ERFINDUNGEN VERWALTUN ;NOVARTIS AG (CH); NAKAJIMA MOTOWO) 26 August 1999 (1999-08-26) * abstract * * page 1, paragraph 1 * * page 18, paragraph 3 * * page 19, paragraph 7 - page 20, paragraph 1 * * page 26, paragraph 6 *	1,2,4, 10,11, 14-17	
X	US 5 892 112 A (GROBELNY DAMIAN ET AL) 6 April 1999 (1999-04-06) * abstract * * column 2, line 42 - line 49 * * column 6, line 20 - line 24 * * column 7, line 18 - line 23 * * column 24, line 38 - line 50 * * column 25, line 30 - line 46 * * column 26, line 21 - line 24 * * example 50 *	1,2,4, 11,14, 16,17	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
X	WO 99 49871 A (UNIV NEW YORK) 7 October 1999 (1999-10-07) * abstract * * page 2, line 12 - line 28 * * page 5, line 15 - line 24 * * page 7, line 12 - page 8, line 2 * * page 9, line 1 - line 8 * * page 13, line 3 - line 11 * * page 14, line 4 - line 14 * * claims 1,7-11,13,17-21 *	1,2,4, 10,11, 14-17	

EPO FORM 1502 01.92 (P04C10)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 11 4909

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

18-12-2000

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9958128 A	18-11-1999	AU 3834899 A	29-11-1999
EP 0623676 A	09-11-1994	AT 170560 T	15-09-1998
		AU 648505 B	28-04-1994
		AU 5638890 A	18-12-1990
		CA 2017166 A	19-11-1990
		DE 69032609 D	08-10-1998
		DE 69032609 T	06-05-1999
		DK 398753 T	01-02-1999
		EP 0398753 A	22-11-1990
		ES 2123495 T	16-01-1999
		JP 2877509 B	31-03-1999
		JP 4500683 T	06-02-1992
		SG 48766 A	18-05-1998
		SG 43824 A	14-11-1997
		WO 9014363 A	29-11-1990
		US 5714465 A	03-02-1998
WO 9942443 A	26-08-1999	AU 2923599 A	06-09-1999
		EP 1053226 A	22-11-2000
		NO 20003565 A	03-10-2000
US 5892112 A	06-04-1999	US 5270326 A	14-12-1993
		US 5114953 A	19-05-1992
		US 5268384 A	07-12-1993
		US 5239078 A	24-08-1993
		US 5189178 A	23-02-1993
		US 5183900 A	02-02-1993
		AU 1000399 A	04-03-1999
		AU 1604995 A	08-08-1995
		CA 2158760 A	27-07-1995
		EP 0690841 A	10-01-1996
		JP 9501183 T	04-02-1997
		WO 9519965 A	27-07-1995
		US 5773438 A	30-06-1998
		AU 6554294 A	24-10-1994
		AU 8311898 A	28-01-1999
		CA 2160139 A	13-10-1994
		EP 0692931 A	24-01-1996
		JP 8511509 T	03-12-1996
		WO 9422309 A	13-10-1994
		AT 164767 T	15-04-1998
		AU 652016 B	11-08-1994
		AU 9135191 A	25-06-1992
		CA 2096223 A	22-05-1992
		DE 69129236 D	14-05-1998

EPO FORM P0458

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 11 4909

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

18-12-2000

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5892112 A		DE 69129236 T	17-09-1998
		EP 0558681 A	08-09-1993
		ES 2115668 T	01-07-1998
		JP 6102626 B	14-12-1994
		NO 931803 A	18-05-1993
		WO 9209282 A	11-06-1992
		AU 3433293 A	03-08-1993
		EP 0663823 A	26-07-1995
		JP 7503007 T	30-03-1995
		WO 9313741 A	22-07-1993
		US 5696147 A	09-12-1997
		AT 157963 T	15-09-1997
		AU 661289 B	20-07-1995
		AU 9089791 A	25-06-1992
		CA 2096225 A	21-02-1993
		DE 69127630 D	16-10-1997
		DE 69127630 T	09-04-1998
		EP 0558635 A	08-09-1993
		ES 2109335 T	16-01-1998
		JP 7080825 B	30-08-1995
		JP 6511468 T	22-12-1994
		NO 931844 A	09-07-1993
		WO 9209563 A	11-06-1992
		AU 662504 B	07-09-1995
		AU 9095891 A	25-06-1992
		CA 2096221 A	22-05-1992

WO 9949871 A	07-10-1999	AU 3457699 A	18-10-1999

EPO FORM 10169

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82